GALAPAGOS NV/S (GLPG) Earning Somewhat Favorable News Coverage, Report Finds
Media coverage about GALAPAGOS NV/S (NASDAQ:GLPG) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. GALAPAGOS NV/S earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.1135419077871 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
GLPG stock opened at $95.35 on Monday. The stock has a market capitalization of $4.89 billion, a P/E ratio of -36.12 and a beta of 2.01. GALAPAGOS NV/S has a 52 week low of $84.13 and a 52 week high of $121.09.
GALAPAGOS NV/S (NASDAQ:GLPG) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.91) by $0.41. The business had revenue of $59.27 million during the quarter, compared to the consensus estimate of $50.58 million. GALAPAGOS NV/S had a negative return on equity of 13.26% and a negative net margin of 70.80%. equities analysts expect that GALAPAGOS NV/S will post -3.12 EPS for the current year.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: Tariff
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.